India's largest animal-health company: veterinary APIs and finished drug formulations, sold globally.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 354 | +7.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 13.0 | −2.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 21.0 | +23.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 8.32 | +6.4 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 6.58 | −2.0 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 52.93 | −105.8 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Guidance
2 of 3 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Combined EBITDA Margin | Combined entity margin profile closer to 20% by FY27 | Q4 FY25 | Maintained margin at 21.6% and reiterated guidance of 20-22% range, confirming sustained achievement. | Achieved |
| Merger Synergies | INR 50-60 crores in 12-18 months | Q3 FY26 | No specific update provided on the synergy realization against the revised target of INR 125-150 crores. | Ghosted |
| Combined Top Line | INR 4,000 crore in the next 2 to 2.5 years | Q4 FY25 | New guidance for FY27 revenue growth is 13-15%. On the FY26 base of INR 3,420 cr, this projects to INR 3,865-3,933 cr, which is below the INR 4,000 cr target. Promise is now at risk. | At Risk |
1 of Viyash Scientific Limited's 14 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹202.06 on 24 Oct 2025 → ₹214.87. High ₹294.15 (3 Jul 2026), low ₹179.89 (23 Mar 2026).
Overview
Based on the company's own presentations, annual report and earnings calls.
Viyash Scientific Limited (formerly SeQuent Scientific) is an integrated animal (veterinary) health company that develops, manufactures and markets Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) for livestock, poultry and companion animals, spanning therapeutic areas such as antibiotics, anthelmintics, pain management, nutrition and gut health. It runs manufacturing and R&D sites across India, Spain, Turkey and Brazil, and sells through direct front-end teams and distribution partnerships across Europe, Emerging Markets, USA and India, marketing formulations under its Alivira animal-health brand. In FY25/26 it completed a strategic merger with Viyash Life Sciences Private Limited, combining research, manufacturing and supply-chain capabilities into one integrated global animal-health platform.
Segments
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
2 of 3 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Combined EBITDA Margin | Combined entity margin profile closer to 20% by FY27 | Q4 FY25 | Maintained margin at 21.6% and reiterated guidance of 20-22% range, confirming sustained achievement. | Achieved |
| Merger Synergies | INR 50-60 crores in 12-18 months | Q3 FY26 | No specific update provided on the synergy realization against the revised target of INR 125-150 crores. | Ghosted |
| Combined Top Line | INR 4,000 crore in the next 2 to 2.5 years | Q4 FY25 | New guidance for FY27 revenue growth is 13-15%. On the FY26 base of INR 3,420 cr, this projects to INR 3,865-3,933 cr, which is below the INR 4,000 cr target. Promise is now at risk. | At Risk |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 14 tracked commitments, with each call’s wording and source.
Call summaries
Viyash Scientific Limited Q1 FY27
Viyash Scientific Limited delivered a strong Q1 FY27 with robust revenue and EBITDA growth, driven by Animal Health and US Human Formulations. The company achieved a virtually debt-free status and is strategically investing in organic R&D and manufacturing, alongside the BioForLife acquisition in Italy. While API revenue was flat this quarter due to timing issues, management anticipates a rebound.
Read the full callVIYASH Q4 FY26
Viyash Scientific Limited reported a transformative FY26, achieving its strongest quarter in Q4 with EBITDA exceeding INR200 crores and a significant 1,324% PAT growth for the full year. The company saw robust revenue growth, particularly in formulations, and substantial margin expansion. Management highlighted successful integration, strategic focus on complex products, and expansion in animal health, while also addressing potential challenges from raw material volatility and complex US market dynamics.
Read the full callVIYASH Q3 FY26
Viyash Scientific Limited reported strong Q3 FY26 results, with significant revenue and EBITDA growth driven by broad-based participation across segments and geographies. The company achieved substantial margin expansion and strengthened its balance sheet, despite one-time merger-related and tax expenses. Management expressed confidence in sustaining 20% EBITDA margins and outlined strategic growth drivers including companion animals and CDMO.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
Net profit, year on year: +24% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 338 | 42 | 328 | 340 | 342 | 372 | 354 |
| Expenses | 44 | 280 | 45 | 279 | 288 | 271 | 310 | 307 |
| Operating profit | -2 | 58 | -3 | 49 | 52 | 70 | 63 | 47 |
| Operating margin | −5.0% | 17.0% | −7.0% | 15.0% | 15.0% | 21.0% | 17.0% | 13.0% |
| Other income | 12 | 13 | 12 | 12 | 16 | -25 | 20 | 15 |
| Interest | 1 | 6 | 1 | 6 | 4 | 4 | 3 | 1 |
| Depreciation | 2 | 32 | 2 | 31 | 31 | 31 | 31 | 32 |
| Profit before tax | 6 | 34 | 6 | 24 | 33 | 11 | 49 | 28 |
| Tax rate | 34.0% | −52.0% | 28.0% | 28.0% | 30.0% | 101.0% | 27.0% | 25.0% |
| Net profit | 4 | 51 | 4 | 17 | 23 | 0 | 36 | 21 |
| EPS (₹ per share) | 0.17 | 2.04 | 0.17 | 0.69 | 0.91 | 0 | 0.82 | 0.48 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 1,101 | 168 | 480 | 1,382 |
| Expenses | 1,092 | 195 | 429 | 1,148 |
| Operating profit | 9 | -27 | 51 | 234 |
| Other income | 10 | 39 | 48 | 23 |
| Interest | 26 | 4 | 9 | 17 |
| Depreciation | 43 | 8 | 38 | 124 |
| Profit before tax | -50 | 0 | 52 | 117 |
| Net profit | -31 | 1 | 63 | 76 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 50 | 50 | 50 | 50 | 50 | 87 |
| Reserves | 991 | 1,008 | 1,037 | 2,858 | 759 | 3,102 |
| Borrowings | 17 | 20 | 47 | 205 | 490 | 33 |
| Other liabilities | 66 | 44 | 54 | 406 | 427 | 433 |
| Total liabilities | 1,124 | 1,123 | 1,188 | 3,520 | 1,726 | 3,655 |
| Fixed assets | 67 | 57 | 43 | 1,220 | 628 | 1,162 |
| Capital work in progress | 1 | 2 | 5 | 34 | 5 | 55 |
| Investments | 659 | 633 | 640 | 968 | 0 | 977 |
| Other assets | 397 | 431 | 500 | 1,298 | 1,093 | 1,460 |
| Total assets | 1,124 | 1,123 | 1,188 | 3,520 | 1,726 | 3,655 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 2 | 9 | 38 | -27 | 188 | 119 |
| Cash from investing | 17 | -4 | -51 | 5 | -411 | -107 |
| Cash from financing | -21 | 7 | 0 | 22 | 195 | -7 |
| Net cash flow | -2 | 12 | -13 | 1 | -27 | 5 |
| Free cash flow | -7 | 3 | 29 | -12 | 131 | 50 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 84 | 87 | 22 | 97 | 124 | 146 |
| Inventory days | 154 | 228 | 129 | 117 | 172 | 171 |
| Days payable | 197 | 193 | 99 | 126 | 146 | 182 |
| Cash conversion cycle | 41 | 122 | 53 | 88 | 150 | 136 |
| Working capital days | 65 | 87 | 22 | -5 | 85 | 135 |
| Return on capital employed | 5.0% | 2.0% | −1.0% | 1.0% | 7.0% | 6.0% |
| Dividend payout | 39.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Promoters hold 49.24% as of Sept 2026; institutions added 2.64 pts since Jun 2026.
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 4 holders trimming and 1 off the list — both are in the register beside this.
Named in the Sep 2026 filing
Every holder of Viyash Scientific Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 25.03% | −6.14 pp | |
| 24.21% | −5.93 pp | |
| Mutual fund | 4.05% | newly disclosed |
| 2.74% | unchanged | |
| 2.23% | −0.12 pp | |
| Mutual fund | 1.97% | newly disclosed |
| 1.16% | −0.11 pp | |
| Mutual fund | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Viyash Scientific Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.